Crohn’s disease

These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.

For Colitis and Crohn’s Disease Awareness Week, learn about the challenges of this painful condition—and why Johnson & Johnson continues to seek new treatment options.

Sid Jain, a leader on the pharmaceutical R&D data science team at Johnson & Johnson, knows that new and better treatment options change lives. And being a Crohn’s disease patient himself has supercharged his mission to help revolutionize the research process.

Over the past few decades, advances in the study and treatment of this inflammatory bowel disease have rapidly accelerated. We spoke to the experts to learn the latest about managing Crohn’s disease—and what other potential breakthroughs are on the horizon.

There are trillions of microorganisms living in your gut—and they might just be the key to helping treat diseases like Crohn’s and ulcerative colitis. Meet a researcher who spends her days exploring this microscopic world.

Tackling a triathlon isn’t for the faint of heart. But Mark van Ooij, an Associate Scientific Director for Janssen Vaccines & Prevention B.V., is doing just that—and he’s taking what he’s learned from his disease to propel him forward.

An avid runner. A fireman. A college student. What they share in common may surprise you—and the battle to get their lives back after debilitating diagnoses will inspire you.